Section 4 of 6
Clinical evidence
82 evidence topics · 13 sources
Study summaries
NORSE TWO
Objective
Pivotal efficacy and safety trial supporting the nAMD indication
“This was a prospective multicenter, randomized, double-masked, active-controlled study, the aim of which was to demonstrate the efficacy and safety of intravitreal ONS-5010 (bevacizumab-vikg) in eyes with neovascular age-related macular degeneration (nAMD). This was a phase III trial on ONS-5010 (NORSE TWO).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Summary: number of trial sites
The company's own announcement of the 12-month NORSE TWO results described the trial as enrolling 228 subjects across 39 clinical trial sites in the United States.
NORSE TWO trial dates and location
| Field | Quoted record |
|---|---|
| Study Start Date | “2019-06-25” |
| Primary Completion Date | “2021-06-07” |
| Study Completion Date | “2021-07-08” |
| Overall Status | “Completed” |
| Country | “United States” |
Study design
NORSE TWO study design
| Field | Quoted record |
|---|---|
| Allocation | “Randomized” |
| Intervention Model | “Parallel Assignment” |
| Masking | “Double” |
| Who Masked | “Participant”, “Outcomes Assessor” |
| Primary Purpose | “Treatment” |
| Phase | “Phase 3” |
| Enrollment | “228” |
Eligibility criteria
NORSE TWO eligibility criteria
“Have edema involving the fovea” (opens the source at this quote in a new tab)
“Current vitreous haemorrhage in the study eye” (opens the source at this quote in a new tab)
“Treatment-naïve nAMD patients aged 50 years and older with a best-corrected distance visual acuity (BCVA) of 25 to 67 Early Treatment Diabetic Retinopathy Study (ETDRS) letters and evidence of disease activity were included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
NORSE TWO treatment regimens
“Patients randomized to ONS-5010 received monthly intravitreal doses of 1.25 mg of ONS-5010, bevacizumab-vikg (Outlook Therapeutics) for 12 months. Patients randomized to ranibizumab received 0.50 mg of ranibizumab on days 0, 30, 60, 150, and 240 based on the PIER study dosing regimen.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
| Field | Quoted record |
|---|---|
| Bevacizumab (ONS-5010) dose | “1.25 mg, intravitreal injection” |
| Ranibizumab dose | “0.5mg, intravitreal injection” |
Study outcomes
Rationale for using ETDRS best corrected visual acuity gain as the primary endpoint
Primary endpoint: proportion gaining 15 or more ETDRS letters at 11 months
Statistical analysis description
Number of participants (Planned and analyzed)
Summary: number of trial sites
The company's own announcement of the 12-month NORSE TWO results described the trial as enrolling 228 subjects across 39 clinical trial sites in the United States.
NORSE TWO participants analyzed by arm
| Field | Ranibizumab 0.5 mg Once Monthly x 3 Months then every 3 Months (N = 115) | LYTENAVA 1.25 mg Once Monthly (N = 113) |
|---|---|---|
| Number of subjects, n/N (%) | “24/104 (23.1)” | “45/108 (41.7)” |
| Risk difference | “0.1859” | |
| 95% CI | “0.0442, 0.3086” |
NORSE TWO statistical results summary
| Field | Quoted record |
|---|---|
| Risk difference | “0.1859” |
| 95% CI | “0.0442, 0.3086” |
Description of analysis sets
Summary: intent-to-treat and per-protocol analyses
The company's own 12-month results announcement described the primary endpoint as met in both an intent-to-treat (ITT) primary dataset (23% ranibizumab vs. 41% bevacizumab-vikg, p=0.0052) and a secondary per-protocol (PP) dataset (24% ranibizumab vs. 41% bevacizumab-vikg, p=0.04).
NORSE TWO analysis set composition
“One hundred thirteen participants were included in the ONS-5010 group and 115 participants were included in the ranibizumab group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All 228 randomized patients were included in the ITT and safety populations (113 patients in the ONS-5010 group and 115 patients in the ranibizumab group), and 163 patients were included in the PP population (85 and 78 patients in the ONS-5010 and ranibizumab groups, respectively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
NORSE TWO participants included in each arm
“One hundred thirteen participants were included in the ONS-5010 group and 115 participants were included in the ranibizumab group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
| Field | Ranibizumab 0.5 mg Once Monthly x 3 Months then every 3 Months (N = 115) | LYTENAVA 1.25 mg Once Monthly (N = 113) |
|---|---|---|
| Number of subjects, n/N (%) | “24/104 (23.1)” | “45/108 (41.7)” |
Completion and reasons for discontinuation
“A total of 228 patients were randomized at 39 study centers across the US. Of those, 198 (86.8%) completed the study. The three most frequently reported reasons for study discontinuation were withdrawal of consent (4.8%), AEs (3.5%), and other reasons (1.8%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the ONS-5010 group, nine patients discontinued the treatment and withdrew from the study (five because of AEs, three lost to follow-up, and one withdrew voluntarily); one patient completed treatment but withdrew from the study; and two patients discontinued treatment but completed the study. In the ranibizumab group, 20 patients discontinued the treatment and withdrew from the study (10 due to voluntary withdrawal, five because of AEs, three because of lack of effectiveness, and three for other reasons); one patient discontinued treatment but completed the study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
NORSE TWO baseline age
“Treatment-naïve nAMD patients aged 50 years and older with a best-corrected distance visual acuity (BCVA) of 25 to 67 Early Treatment Diabetic Retinopathy Study (ETDRS) letters and evidence of disease activity were included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
NORSE TWO baseline demographics and disease characteristics
Efficacy results
Summary: mean change in best corrected visual acuity from baseline to Month 11
The company's own 12-month results announcement reported that the secondary endpoint of mean BCVA change from baseline to Month 11 was also statistically significant, at p=0.0043 in the intent-to-treat dataset.
NORSE TWO primary endpoint result
| Field | Ranibizumab 0.5 mg Once Monthly x 3 Months then every 3 Months (N = 115) | LYTENAVA 1.25 mg Once Monthly (N = 113) |
|---|---|---|
| Number of subjects, n/N (%) | “24/104 (23.1)” | “45/108 (41.7)” |
| Risk difference | “0.1859” | |
| 95% CI | “0.0442, 0.3086” |
“Respectively, 41.7% and 23.1% of patients gained ≥ 15 letters (3 lines) of visual acuity, with a risk difference of 0.1859 [95% CI = 0.0442, 0.3086]; P = 0.0052. The change in BCVA from baseline to 11 months was found to be 11.2 ± 12.19 and 5.8 ± 14.80 ETDRS letters, respectively. The number of patients gaining ≥ 5 and ≥ 10 letters and patients losing < 15 letters was significantly higher in the ONS-5010 group. Similarly, patients with a Snellen visual acuity equivalent of 20/200 (35 ETDRS letters) or worse at 11 months were significantly fewer in the ONS-5010 group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
NORSE TWO secondary endpoint responder analysis
| Parameter, n/N (%) | Ranibizumab (n = 115) | ONS-5010 (n = 113) |
|---|---|---|
| Subjects gaining ≥5 letters from baseline at 11 months | “53/104 (51.0)”View highlighted excerpt for this quote | “74/108 (68.5)”View highlighted excerpt for this quote |
| Subjects gaining ≥10 letters from baseline at 11 months | “36/104 (34.6)”View highlighted excerpt for this quote | “61/108 (56.5)”View highlighted excerpt for this quote |
| Subjects losing <15 letters from baseline at 11 months | “86/104 (82.7)”View highlighted excerpt for this quote | “101/108 (93.5)”View highlighted excerpt for this quote |
| Subjects with a visual acuity Snellen equivalent of 20/200 or worse at 11 months | “25/104 (24.0)”View highlighted excerpt for this quote | “14/108 (13.0)”View highlighted excerpt for this quote |
NORSE TWO mean BCVA change by complementary analysis
“When calculated using the trimmed means fixed approach, the least squares (LS) mean change in BCVA from baseline to 11 months was 19.310 letters in the ONS-5010 group and 14.575 letters in the ranibizumab group (LS mean difference of 4.735 [95% CI = 1.306, 8.163]; P = 0.0035). When calculated using the trimmed means adaptive approach, the LS mean change in BCVA from baseline to 11 months was 13.640 letters in the ONS-5010 group and 5.770 letters in the ranibizumab group. The difference observed between study treatment groups was significant, with an LS mean difference of 7.870 (95% CI = 4.536, 12.599; P = 0.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Summary: ocular adverse events and inflammation
The company's own 12-month results announcement reported only one subject with an ocular inflammation adverse event following exposure to bevacizumab-vikg, one related ocular serious adverse event in the bevacizumab-vikg arm (which resolved), and conjunctival hemorrhage as the most common ocular adverse event, and described the safety database as consistent with previously published bevacizumab safety results.
NORSE TWO serious ocular adverse event and most common adverse event by arm
“Only one patient in the ONS-5010 group had a study-related serious ocular adverse event (SAE), namely, elevated intraocular pressure. The most common adverse event in the ONS-5010 group was conjunctival hemorrhage (8.8%), and reduced visual acuity in the ranibizumab group (12.2%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
NORSE TWO treatment-emergent adverse event summary
| Criteria | Ranibizumab (n = 115), n (%) | ONS-5010 (n = 113), n (%) |
|---|---|---|
| At least 1 TEAE | “85 (73.9%)”View highlighted excerpt for this quote | “85 (75.2%)”View highlighted excerpt for this quote |
| At least 1 TEAE related to study drug/study procedure | “9 (7.8%)”View highlighted excerpt for this quote | “21 (18.6%)”View highlighted excerpt for this quote |
| At least 1 ocular TEAE | “61 (53.0%)”View highlighted excerpt for this quote | “59 (52.2%)”View highlighted excerpt for this quote |
| At least 1 serious TEAE | “16 (13.9%)”View highlighted excerpt for this quote | “14 (12.4%)”View highlighted excerpt for this quote |
| At least 1 TEAE leading to discontinuation | “5 (4.3%)”View highlighted excerpt for this quote | “2 (1.8%)”View highlighted excerpt for this quote |
NORSE TWO deaths during the study
“A total of five patients died, including three in the ONS-5010 group and two in the ranibizumab group. The events that resulted in death were COVID-19 and respiratory failure (both occurring in the same patient of the ONS-5010 group), myocardial infarction and death due to COVID-19 (each occurring in different patients of the ONS-5010 group), and cardiac arrest and cardiac death (each occurring in different patients in the ranibizumab group). These events were not considered by the investigators to be related to the study treatment/study procedure.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pooled ocular adverse reactions across the LYTENAVA clinical development program (five trials)
Study limitations
Summary: comparator dosing regimen
NORSE TWO compared monthly LYTENAVA dosing for one year against a ranibizumab regimen of three monthly loading doses followed by quarterly dosing, rather than against monthly ranibizumab throughout the study.
Authors' rationale for the unequal dosing regimens
“The different dosing regimen between the two groups is not considered a limitation of the study given that the aim of the study was to demonstrate the effect of bevacizumab. One reason for spacing doses in the ranibizumab group was to replicate a more realistic clinical dosing schedule. Furthermore, according to both the IVAN and CATT study, spaced dosing of ranibizumab was shown to be as effective as monthly dosing.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“While clinicians often treat nAMD with greater frequency than the ranibizumab arm of the NORSE TWO study, the study was designed to meet a regulatory endpoint of comparison to a previously approved treatment dosing regimen in order to demonstrate the existence of a treatment effect for ONS-5010.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Greater injection frequency as a possible driver of the higher treatment-related adverse event rate
“The frequency of TEAEs considered by the investigators to be related to the study treatment/study procedure was greater in the ONS-5010 group compared with the ranibizumab group (18.6% [21 patients] vs 7.8% [9 patients]). Hypothetically, this may be due to a greater number of injections in the ONS-5010 group (12 injections in the ONS-5010 group versus five injections in the ranibizumab group).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
NORSE EIGHT
Objective
Second pivotal trial supporting the NORSE TWO efficacy finding
Location and study date
NORSE EIGHT trial dates and location
| Field | Quoted record |
|---|---|
| Study Start Date | “2024-01-24” |
| Primary Completion Date | “2024-11-07” |
| Study Completion Date | “2024-12-05” |
| Overall Status | “Completed” |
| Country | “United States” |
Study design
NORSE EIGHT study design
| Field | Quoted record |
|---|---|
| Allocation | “N/A” |
| Intervention Model | “Parallel Assignment” |
| Masking | “Triple” |
| Who Masked | “Participant”, “Investigator”, “Outcomes Assessor” |
| Primary Purpose | “Treatment” |
| Phase | “Phase 3” |
| Enrollment | “400” |
Eligibility criteria
Treatment
NORSE EIGHT treatment regimens
| Field | Quoted record |
|---|---|
| ONS-5010 bevacizumab dose | “1.25 mg, intravitreal injection” |
| Ranibizumab dose | “0.5mg, intravitreal injection” |
Study outcomes
Rationale for using mean change in ETDRS best corrected visual acuity as the primary endpoint
Primary endpoint design as a non-inferiority comparison
Primary endpoint: mean change in ETDRS BCVA from baseline at Week 8
Anatomic (pharmacodynamic) outcome: central retinal/foveal thickness
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
Summary: baseline visual acuity
The LYTENAVA arm had a mean baseline BCVA of 58.8 ETDRS letters.
Efficacy results
Summary: preliminary topline Week 8 result (November 2024 announcement)
Before the label's final analysis, the company's preliminary topline announcement reported a mean BCVA increase of “+4.2 letters” for ONS-5010 versus “+6.3 letters” for ranibizumab at Week 8, a difference it described as “-2.257 BCVA letters” (95% CI -4.044, -0.470); these preliminary figures differ slightly from the final Week 8 result in the approved label (Section 3.1.2.8.3 above).
Summary: BCVA gains over time and anatomic response
Mean BCVA improved progressively from baseline for the LYTENAVA arm: approximately +3.3 letters at month 1 (week 4), +4.2 letters at month 2 (week 8), and +5.5 letters at month 3 (week 12). Central retinal thickness decreased by approximately 123.9 microns in the LYTENAVA arm and 127.3 microns in the ranibizumab arm at week 12, an anatomic response the companies described as comparable between arms.
NORSE EIGHT week 8 BCVA result
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
NORSE EIGHT ocular adverse events
Study limitations
Summary: primary endpoint not met at the pre-specified timepoint
NORSE EIGHT did not meet its pre-specified non-inferiority margin of -3.5 letters for the primary endpoint of mean change in BCVA at Week 8, although the LS mean difference at Week 12 (a secondary, non-primary timepoint) was within the non-inferiority margin.
NORSE ONE
Objective
NORSE ONE trial title and design
Location and study date
NORSE ONE trial dates and location
| Field | Quoted record |
|---|---|
| Study Start Date | “2018-10-01” |
| Primary Completion Date | “2020-07-23” |
| Study Completion Date | “2020-08-13” |
| Overall Status | “Completed” |
| Country | “Australia” |
Study design
NORSE ONE study design
| Field | Quoted record |
|---|---|
| Allocation | “Randomized” |
| Intervention Model | “Parallel Assignment” |
| Masking | “Double” |
| Who Masked | “Participant”, “Outcomes Assessor” |
| Primary Purpose | “Treatment” |
| Phase | “Phase 3” |
| Enrollment | “61” |
Eligibility criteria
NORSE ONE eligibility criteria
“Best corrected visual acuity of 20/40 to 20/320” (opens the source at this quote in a new tab)
“Have edema involving the fovea” (opens the source at this quote in a new tab)
“Be free of foveal scarring” (opens the source at this quote in a new tab)
“Be free of foveal atrophy” (opens the source at this quote in a new tab)
Treatment
NORSE ONE treatment regimens
| Field | Quoted record |
|---|---|
| Bevacizumab (ONS-5010) dose | “1.25 mg, intravitreal injection” |
| Ranibizumab dose | “0.5mg, intravitreal injection” |
Study outcomes
Rationale for using ETDRS best corrected visual acuity gain as the primary endpoint
NORSE ONE primary endpoint definition
NORSE ONE primary and secondary outcome measures
Statistical analysis description
Number of participants (Planned and analyzed)
Summary: participants analyzed per arm
The company's topline results announcement described the ONS-5010 arm as 25 patients and the ranibizumab arm as 23 patients within the 61-patient trial.
Description of analysis sets
No evidence found.
Results
Participant disposition
Baseline characteristics
No evidence found.
Efficacy results
Summary: proportion gaining 15 or more letters at Month 11
The company's topline results announcement reported that 2 of 25 (8%) patients on the ONS-5010 arm and 5 of 23 (22%) patients on the ranibizumab arm gained more than 15 letters of best corrected visual acuity at Month 11, favoring ranibizumab numerically in this small trial.
Summary: treatment-naive subgroup
Among treatment-naive participants, the announcement reported 2 of 6 (33%) patients on the ONS-5010 arm and 4 of 13 (31%) patients on the ranibizumab arm gaining more than 15 letters at Month 11.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Summary: safety comparable between arms
The company's topline results announcement reported no statistical differences in safety between ranibizumab and ONS-5010, and zero cases of ocular inflammation.
Study limitations
Summary: small comparator trial with results diverging from NORSE TWO
NORSE ONE was a small, 61-patient clinical experience trial in Australia, roughly 30 subjects per arm, in which a numerically smaller proportion of the ONS-5010 arm than the ranibizumab arm gained 15 or more letters, a result not repeated in the larger pivotal NORSE TWO trial.
NORSE THREE
Objective
Summary: purpose of the trial
The company's safety results announcement described NORSE THREE as an open-label safety study conducted to ensure an adequate number of safety exposures to ONS-5010 were available for the initial BLA submission to the FDA.
Location and study date
NORSE THREE trial dates and location
| Field | Quoted record |
|---|---|
| Study Start Date | “2020-10-01” |
| Primary Completion Date | “2021-02-10” |
| Study Completion Date | “2021-02-10” |
| Overall Status | “Completed” |
| Country | “United States” |
Study design
Summary: enrollment and disease mix
The company's safety results announcement described NORSE THREE as enrolling 197 treatment-naive and previously treated subjects with wet AMD, diabetic macular edema (DME), or branch retinal vein occlusion (BRVO), to add safety exposures ahead of the initial BLA submission.
NORSE THREE study design
| Field | Quoted record |
|---|---|
| Allocation | “N/A” |
| Intervention Model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
| Primary Purpose | “Treatment” |
| Phase | “Phase 3” |
| Enrollment | “197” |
Eligibility criteria
NORSE THREE eligibility criteria
Treatment
NORSE THREE treatment regimen
| Field | Quoted record |
|---|---|
| Bevacizumab (ONS-5010) dose | “1.25 mg, intravitreal injection” |
Study outcomes
Rationale for using adverse event incidence as the primary endpoint
NORSE THREE primary outcome measure
Statistical analysis description
Number of participants (Planned and analyzed)
Summary: enrollment
The company's safety results announcement described NORSE THREE as enrolling 197 treatment-naive and previously treated subjects.
Description of analysis sets
No evidence found.
Results
Participant disposition
Summary: enrollment and adverse event incidence
The company's safety results announcement reported that 20 of the 197 enrolled patients (10%) experienced an adverse event in the study eye, most commonly associated with the injection procedure rather than the drug itself.
Baseline characteristics
No evidence found.
Efficacy results
Not applicable.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Summary: adverse event incidence and comparison to prior bevacizumab safety data
Of the 197 enrolled patients, 20 (10%) experienced an adverse event in the study eye, most commonly associated with the injection procedure. The company described the safety profile as showing no unexpected trends and as consistent with prior published bevacizumab safety data, including the 2011 CATT study.
NORSE THREE absence of serious adverse events
Study limitations
Summary: open-label, single-arm design
NORSE THREE had no comparator or masking, so its adverse-event findings cannot be compared statistically with a control arm; it was designed only to add safety exposures to the overall LYTENAVA safety database ahead of the initial BLA submission.
NORSE SEVEN
Objective
Location and study date
NORSE SEVEN trial dates and location
| Field | Quoted record |
|---|---|
| Study Start Date | “2021-11-15” |
| Primary Completion Date | “2027-12” |
| Study Completion Date | “2027-12” |
| Overall Status | “Active, not recruiting” |
| Country | “United States” |
Study design
NORSE SEVEN study design
| Field | Quoted record |
|---|---|
| Allocation | “N/A” |
| Intervention Model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
| Primary Purpose | “Treatment” |
| Phase | “Phase 3” |
| Enrollment | “120” |
Eligibility criteria
NORSE SEVEN eligibility criteria
Treatment
NORSE SEVEN treatment regimen
| Field | Quoted record |
|---|---|
| Bevacizumab (ONS-5010) dose | “1.25 mg, intravitreal injection” |
Study outcomes
Rationale for using adverse event incidence as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
NORSE SEVEN planned enrollment
| Field | Quoted record |
|---|---|
| Enrollment | “120” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Not applicable.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary: ongoing, single-arm bridging study
NORSE SEVEN is a single-arm, open-label study comparing ONS-5010 supplied in vials versus a pre-filled syringe, with no ranibizumab or placebo comparator; ClinicalTrials.gov lists the trial as active, not recruiting, with an estimated primary completion date of December 2027, so its results are not yet available.